Supernus Pharmaceuticals Inc (SUPN)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 661,817 | 607,521 | 673,056 | 560,079 | 500,962 |
| Receivables | US$ in thousands | 142,077 | 144,155 | 165,497 | 148,932 | 140,877 |
| Receivables turnover | 4.66 | 4.21 | 4.07 | 3.76 | 3.56 |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $661,817K ÷ $142,077K
= 4.66
Supernus Pharmaceuticals Inc has demonstrated a consistent improvement in its receivables turnover over the past five years. The receivables turnover ratio increased from 3.56 in December 31, 2020, to 4.66 in December 31, 2024. This indicates that the company is collecting its accounts receivables more efficiently and frequently, which is a positive sign of its liquidity and ability to manage credit effectively. The rising trend in receivables turnover suggests that Supernus Pharmaceuticals Inc has been successful in managing and converting its credit sales into cash, potentially indicating effective credit policies and timely collection procedures. Overall, the improving receivables turnover ratio is a favorable indicator of Supernus Pharmaceuticals Inc's financial health and operational efficiency.
Peer comparison
Dec 31, 2024